ReviewDrugs in context2026
Cloperastine in paediatric and adult cough management: a historical narrative review.
Review in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cough is a common symptom associated with many mild and severe medical conditions such as acute and chronic respiratory disorders. However, it can also be linked to extrapulmonary pathologies such as gastroesophageal reflux. Whilst often beneficial in clearing secretions, a persistent dry cough can significantly impair quality of life and necessitate pharmacological intervention. Cloperastine, a non-opioid antitussive agent with central and peripheral mechanisms of action, is widely used in clinical practice. This narrative review critically examines the pharmacological properties, clinical efficacy and safety profile of cloperastine in the management of non-productive cough across adult and paediatric populations. In preclinical studies, cloperastine demonstrated antitussive efficacy 1.9 times greater than that of codeine, without narcotic effects. Moreover, cloperastine exhibits a quarter of the antihistaminic potency of diphenhydramine, does not impair mucociliary clearance and relaxes bronchial smooth muscle. Across more than 40 clinical studies, cloperastine was consistently effective in reducing cough frequency and intensity, with typical doses of 20-60 mg/day (hydrochloride) or 10-106 mg/day (fendizoate) in adults, and 6-106 mg/day (fendizoate) or 5-400 mg/day (hydrochloride) in children, where dosing was fixed or adjusted for age or weight. The onset of action was observed as early as 20 minutes. It demonstrated superior or comparable efficacy to codeine, clobutinol, dextromethorphan, levodropropizine, butamirate and dihydrocodeine. In paediatric populations, it improved sleep quality and sputum quality. Cloperastine is a well-tolerated and effective antitussive with a rapid onset, favourable safety profile and low risk of central nervous system side-effects, supporting its role as a valuable therapeutic option for dry cough across all ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.